Search results
Taking into account the PRAC Assessment Report on the PSUR(s) for leuprorelin (depot formulations), the scientific conclusions are as follows: In view of available data on Idiopathic intracranial hypertension from the literature, clinical trials and
3 cze 2022 · The development of second-generation leuprorelin acetate (LA) depot formulation (Eligard®, Recordati S.p.A) allowed a consistent and controlled release of leuprorelin between injections and a more efficient reduction of testosterone levels with respect to conventional LHRH agonists.
There have been reports for medication errors possibly leading to lack of effect with all leuprorelin containg products. For one product (Eligard) there have been 2,271 cases of handling errors reported
14 cze 2019 · Depot formulations of leuprorelin are used to treat prostate cancer, breast cancer, certain conditions that affect the female reproductive system, and early puberty. Several formulations require complex steps to prepare the injection.
Periodic safety update report single assessments (PSUSAs) are single assessments of related periodic safety update reports (PSURs) for active substances contained in medicines authorised in the European Union (EU).
1 cze 2002 · Leuprorelin acetate has been in clinical use in the palliative treatment of prostate cancer for more than 20 years, but advances continue to be made in terms of convenience and flexibility of...
In humans, administration of leuprorelin acetate results in an initial increase in circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in
